Publications by authors named "Frits Moolenaar"

Claim this Profile
[
[Basic understanding of pharmacokinetics that every doctor should know].
Johannes H Proost, Frits Moolenaar, Pieter A de Graeff

Ned Tijdschr Geneeskd· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury.
Jai Prakash, Martin H de Borst, Marie Lacombe, Frank Opdam, Pieter A Klok, Frits Moolenaar

J Am Soc Nephrol· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis.
Jai Prakash, Martin H de Borst, Annemiek M van Loenen-Weemaes, Marie Lacombe, Frank Opdam, Frits Moolenaar

Pharm Res· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis.
Jai Prakash, Maria Sandovici, Vinay Saluja, Marie Lacombe, Roel Q J Schaapveld, Frits Moolenaar

J Pharmacol Exp Ther· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioanalysis and pharmacokinetics of the p38 MAPkinase inhibitor SB202190 in rats.
Jai Prakash, Vinay Saluja, Jan Visser, Frits Moolenaar, Dirk K F Meijer

J Chromatogr B Analyt Technol Biomed Life Sci· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal-selective delivery and angiotensin-converting enzyme inhibition by subcutaneously administered captopril-lysozyme.
Jai Prakash, Annemiek M van Loenen-Weemaes, Marijke Haas, Johannes H Proost, Dirk K F Meijer, Frits Moolenaar

Drug Metab Dispos· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis.
Willemijn A K M Windt, Jai Prakash, Robbert Jan Kok, Frits Moolenaar, C Alex Kluppel

J Renin Angiotensin Aldosterone Syst· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of anti-proteinuric therapy with angiotensin-converting-enzyme inhibition on renal protein catabolism in the adriamycin-induced nephrotic rat.
Marijke Haas, Eric de Boer, Paul E de Jong, Frits Moolenaar, Dirk K F Meijer

Clin Sci (Lond)· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Specific drug delivery to the kidney.
Marijke Haas, Frits Moolenaar, Dirk K F Meijer, Dick de Zeeuw

Cardiovasc Drugs Ther· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats.
R Folgert G Haverdings, Marijke Haas, Gerjan Navis, Anne-Miek Van Loenen-Weemaes, Dirk K F Meijer, Frits Moolenaar

Br J Pharmacol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting of doxorubicin to the urinary bladder of the rat shows increased cytotoxicity in the bladder urine combined with an absence of renal toxicity.
Marijke Haas, Frits Moolenaar, Angela Elsinga, Els A Van der Wouden, Paul E de Jong

J Drug Target· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis